{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:34:41Z","timestamp":1794580481880,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["104807\/Z\/14\/Z"],"award-info":[{"award-number":["104807\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIHR Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London. University College London Therapeutic Acceleration Support fund."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Wiskott-Aldrich syndrome (WAS) is an X-linked primary immunodeficiency with severe platelet abnormalities and complex immunodeficiency. Although clinical gene therapy approaches using lentiviral vectors have produced encouraging results, full immune and platelet reconstitution is not always achieved. Here we show that a CRISPR\/Cas9-based genome editing strategy allows the precise correction of\n                    <jats:italic>WAS<\/jats:italic>\n                    mutations in up to 60% of human hematopoietic stem and progenitor cells (HSPCs), without impairing cell viability and differentiation potential. Delivery of the editing reagents to WAS HSPCs led to full rescue of WASp expression and correction of functional defects in myeloid and lymphoid cells. Primary and secondary transplantation of corrected WAS HSPCs into immunodeficient mice showed persistence of edited cells for up to 26 weeks and efficient targeting of long-term repopulating stem cells. Finally, no major genotoxicity was associated with the gene editing process, paving the way for an alternative, yet highly efficient and safe therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41467-020-17626-2","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T06:06:55Z","timestamp":1597212415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":131,"title":["Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott -\u00a0Aldrich Syndrome"],"prefix":"10.1038","volume":"11","author":[{"given":"Rajeev","family":"Rai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Romito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Rivers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Turchiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Blattner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Vetharoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Ladon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffroy","family":"Andrieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Zinicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Leon-Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1776-1984","authenticated-orcid":false,"given":"Giorgia","family":"Santilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6097-6115","authenticated-orcid":false,"given":"Adrian J.","family":"Thrasher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4735-2121","authenticated-orcid":false,"given":"Alessia","family":"Cavazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"17626_CR1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1586\/1744666X.2015.1062366","volume":"11","author":"AJ Worth","year":"2015","unstructured":"Worth, A. J. & Thrasher, A. J. Current and emerging treatment options for Wiskott-Aldrich syndrome. Expert Rev. Clin. Immunol.11, 1015\u20131032 (2015).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"17626_CR2","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-05-1592","volume":"104","author":"Y Jin","year":"2004","unstructured":"Jin, Y. et al. Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype\/genotype correlation. Blood104, 4010\u20134019 (2004).","journal-title":"Blood"},{"key":"17626_CR3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nri2724","volume":"10","author":"AJ Thrasher","year":"2010","unstructured":"Thrasher, A. J. & Burns, S. O. WASP: a key immunological multitasker. Nat. Rev. Immunol.10, 182\u2013192 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"17626_CR4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbmt.2008.10.007","volume":"15","author":"HD Ochs","year":"2009","unstructured":"Ochs, H. D., Filipovich, A. H., Veys, P., Cowan, M. J. & Kapoor, N. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol. Blood Marrow Transplant.15, 84\u201390 (2009).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"17626_CR5","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0022-3476(05)82002-5","volume":"125","author":"KE Sullivan","year":"1994","unstructured":"Sullivan, K. E., Mullen, C. A., Blaese, R. M. & Winkelstein, J. A. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J. Pediatr.125, 876\u2013885 (1994).","journal-title":"J. Pediatr."},{"key":"17626_CR6","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2010-11-319376","volume":"118","author":"D Moratto","year":"2011","unstructured":"Moratto, D. et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood118, 1675\u20131684 (2011).","journal-title":"Blood"},{"key":"17626_CR7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1182\/blood-2007-03-076679","volume":"111","author":"H Ozsahin","year":"2008","unstructured":"Ozsahin, H. et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood111, 439\u2013445 (2008).","journal-title":"Blood"},{"key":"17626_CR8","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/bmt.2012.31","volume":"47","author":"CR Shin","year":"2012","unstructured":"Shin, C. R. et al. Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome. Bone Marrow Transplant.47, 1428\u20131435 (2012).","journal-title":"Bone Marrow Transplant."},{"key":"17626_CR9","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1003548","volume":"363","author":"K Boztug","year":"2010","unstructured":"Boztug, K. et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. New Engl. J. Med.363, 1918\u20131927 (2010).","journal-title":"New Engl. J. Med."},{"key":"17626_CR10","doi-asserted-by":"crossref","first-page":"227ra233","DOI":"10.1126\/scitranslmed.3007280","volume":"6","author":"CJ Braun","year":"2014","unstructured":"Braun, C. J. et al. Gene therapy for Wiskott-Aldrich syndrome\u2013long-term efficacy and genotoxicity. Sci. Transl. Med.6, 227ra233 (2014).","journal-title":"Sci. Transl. Med."},{"key":"17626_CR11","doi-asserted-by":"crossref","first-page":"1233151","DOI":"10.1126\/science.1233151","volume":"341","author":"A Aiuti","year":"2013","unstructured":"Aiuti, A. et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science341, 1233151 (2013).","journal-title":"Science"},{"key":"17626_CR12","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","volume":"6","author":"F Ferrua","year":"2019","unstructured":"Ferrua, F. et al. Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study. Lancet Haematol.6, e239\u2013e253 (2019).","journal-title":"Lancet Haematol."},{"key":"17626_CR13","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","volume":"313","author":"S Hacein-Bey Abina","year":"2015","unstructured":"Hacein-Bey Abina, S. et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA313, 1550\u20131563 (2015).","journal-title":"JAMA"},{"key":"17626_CR14","doi-asserted-by":"publisher","unstructured":"De Ravin, S. S. et al. CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. Sci. Transl. Med.\nhttps:\/\/doi.org\/10.1126\/scitranslmed.aah3480 (2017).","DOI":"10.1126\/scitranslmed.aah3480"},{"key":"17626_CR15","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/j.celrep.2018.04.103","volume":"23","author":"CY Kuo","year":"2018","unstructured":"Kuo, C. Y. et al. Site-specific gene editing of human hematopoietic stem cells for X-linked hyper-IgM syndrome. Cell Rep.23, 2606\u20132616 (2018).","journal-title":"Cell Rep."},{"key":"17626_CR16","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10080-9","volume":"10","author":"M Pavel-Dinu","year":"2019","unstructured":"Pavel-Dinu, M. et al. Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nat. Commun.10, 1634 (2019).","journal-title":"Nat. Commun."},{"key":"17626_CR17","doi-asserted-by":"publisher","unstructured":"Schiroli, G. et al. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. Sci. Transl. Med.\nhttps:\/\/doi.org\/10.1126\/scitranslmed.aan0820 (2017).","DOI":"10.1126\/scitranslmed.aan0820"},{"key":"17626_CR18","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nbt.3290","volume":"33","author":"A Hendel","year":"2015","unstructured":"Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol.33, 985\u2013989 (2015).","journal-title":"Nat. Biotechnol."},{"key":"17626_CR19","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","volume":"24","author":"CA Vakulskas","year":"2018","unstructured":"Vakulskas, C. A. et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat. Med.24, 1216\u20131224 (2018).","journal-title":"Nat. Med."},{"key":"17626_CR20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1126\/science.1201219","volume":"333","author":"F Notta","year":"2011","unstructured":"Notta, F. et al. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science333, 218\u2013221 (2011).","journal-title":"Science"},{"key":"17626_CR21","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1182\/blood.V98.4.1142","volume":"98","author":"S Burns","year":"2001","unstructured":"Burns, S., Thrasher, A. J., Blundell, M. P., Machesky, L. & Jones, G. E. Configuration of human dendritic cell cytoskeleton by Rho GTPases, the WAS protein, and differentiation. Blood98, 1142\u20131149 (2001).","journal-title":"Blood"},{"key":"17626_CR22","doi-asserted-by":"crossref","first-page":"9648","DOI":"10.1073\/pnas.96.17.9648","volume":"96","author":"S Linder","year":"1999","unstructured":"Linder, S., Nelson, D., Weiss, M. & Aepfelbacher, M. Wiskott-Aldrich syndrome protein regulates podosomes in primary human macrophages. Proc. Natl Acad. Sci. USA96, 9648\u20139653 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"17626_CR23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1365-2141.1998.00767.x","volume":"101","author":"D Zicha","year":"1998","unstructured":"Zicha, D. et al. Chemotaxis of macrophages is abolished in the Wiskott-Aldrich syndrome. Br. J. Haematol.101, 659\u2013665 (1998).","journal-title":"Br. J. Haematol."},{"key":"17626_CR24","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2008-02-140814","volume":"112","author":"A Meyer-Bahlburg","year":"2008","unstructured":"Meyer-Bahlburg, A. et al. Wiskott-Aldrich syndrome protein deficiency in B cells results in impaired peripheral homeostasis. Blood112, 4158\u20134169 (2008).","journal-title":"Blood"},{"key":"17626_CR25","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2008-02-140715","volume":"112","author":"LS Westerberg","year":"2008","unstructured":"Westerberg, L. S. et al. WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. Blood112, 4139\u20134147 (2008).","journal-title":"Blood"},{"key":"17626_CR26","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/blood-2015-07-607903","volume":"127","author":"K Eto","year":"2016","unstructured":"Eto, K. & Kunishima, S. Linkage between the mechanisms of thrombocytopenia and thrombopoiesis. Blood127, 1234\u20131241 (2016).","journal-title":"Blood"},{"key":"17626_CR27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.V94.2.509","volume":"94","author":"E Haddad","year":"1999","unstructured":"Haddad, E. et al. The thrombocytopenia of Wiskott Aldrich syndrome is not related to a defect in proplatelet formation. Blood94, 509\u2013518 (1999).","journal-title":"Blood"},{"key":"17626_CR28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1365-2141.1999.01694.x","volume":"107","author":"M Kajiwara","year":"1999","unstructured":"Kajiwara, M. et al. WASP is involved in proliferation and differentiation of human haemopoietic progenitors in vitro. Br. J. Haematol.107, 254\u2013262 (1999).","journal-title":"Br. J. Haematol."},{"key":"17626_CR29","doi-asserted-by":"publisher","unstructured":"Sereni, L. et al. Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome. J. Allergy Clin. Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2019.03.012 (2019).","DOI":"10.1016\/j.jaci.2019.03.012"},{"key":"17626_CR30","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jaci.2017.12.1000","volume":"142","author":"L Sereni","year":"2018","unstructured":"Sereni, L. et al. Autonomous role of Wiskott-Aldrich syndrome platelet deficiency in inducing autoimmunity and inflammation. J. Allergy Clin. Immunol.142, 1272\u20131284 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"17626_CR31","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1056\/NEJM197804272981701","volume":"298","author":"R Parkman","year":"1978","unstructured":"Parkman, R. et al. Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation. New Engl. J. Med.298, 921\u2013927 (1978).","journal-title":"New Engl. J. Med."},{"key":"17626_CR32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1074-7613(02)00360-6","volume":"17","author":"L Dupre","year":"2002","unstructured":"Dupre, L. et al. Wiskott-Aldrich syndrome protein regulates lipid raft dynamics during immunological synapse formation. Immunity17, 157\u2013166 (2002).","journal-title":"Immunity"},{"key":"17626_CR33","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4049\/jimmunol.173.2.726","volume":"173","author":"V Morales-Tirado","year":"2004","unstructured":"Morales-Tirado, V. et al. Cutting edge: selective requirement for the Wiskott-Aldrich syndrome protein in cytokine, but not chemokine, secretion by CD4+ T cells. J. Immunol.173, 726\u2013730 (2004).","journal-title":"J. Immunol."},{"key":"17626_CR34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaut.2013.10.006","volume":"50","author":"MC Castiello","year":"2014","unstructured":"Castiello, M. C. et al. Wiskott-Aldrich Syndrome protein deficiency perturbs the homeostasis of B-cell compartment in humans. J. Autoimmun.50, 42\u201350 (2014).","journal-title":"J. Autoimmun."},{"key":"17626_CR35","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1038\/mtna.2014.64","volume":"3","author":"TJ Cradick","year":"2014","unstructured":"Cradick, T. J., Qiu, P., Lee, C. M., Fine, E. J. & Bao, G. COSMID: a web-based tool for identifying and validating CRISPR\/Cas off-target sites. Mol. Ther. Nucleic Acids3, e214 (2014).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"17626_CR36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","volume":"33","author":"SQ Tsai","year":"2015","unstructured":"Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol.33, 187\u2013197 (2015).","journal-title":"Nat. Biotechnol."},{"key":"17626_CR37","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nbt.3534","volume":"34","author":"SQ Tsai","year":"2016","unstructured":"Tsai, S. Q., Topkar, V. V., Joung, J. K. & Aryee, M. J. Open-source guideseq software for analysis of GUIDE-seq data. Nat. Biotechnol.34, 483 (2016).","journal-title":"Nat. Biotechnol."},{"key":"17626_CR38","volume":"18","author":"LJ Zhu","year":"2017","unstructured":"Zhu, L. J. et al. GUIDEseq: a bioconductor package to analyze GUIDE-Seq datasets for CRISPR-Cas nucleases. BMC Genomics18, 379 (2017).","journal-title":"BMC Genomics"},{"key":"17626_CR39","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1089\/hum.2017.047","volume":"29","author":"A Gutierrez-Guerrero","year":"2018","unstructured":"Gutierrez-Guerrero, A. et al. Comparison of zinc finger nucleases versus CRISPR-specific nucleases for genome editing of the Wiskott-Aldrich syndrome locus. Hum. Gene Ther.29, 366\u2013380 (2018).","journal-title":"Hum. Gene Ther."},{"key":"17626_CR40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.stemcr.2016.06.003","volume":"7","author":"TJ Laskowski","year":"2016","unstructured":"Laskowski, T. J. et al. Gene correction of iPSCs from a Wiskott-Aldrich syndrome patient normalizes the lymphoid developmental and functional defects. Stem Cell Rep.7, 139\u2013148 (2016).","journal-title":"Stem Cell Rep."},{"key":"17626_CR41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1101\/gad.8.3.363","volume":"8","author":"D Nesic","year":"1994","unstructured":"Nesic, D. & Maquat, L. E. Upstream introns influence the efficiency of final intron removal and RNA 3\u2032-end formation. Genes Dev.8, 363\u2013375 (1994).","journal-title":"Genes Dev."},{"key":"17626_CR42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature13420","volume":"510","author":"P Genovese","year":"2014","unstructured":"Genovese, P. et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature510, 235\u2013240 (2014).","journal-title":"Nature"},{"key":"17626_CR43","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1182\/blood-2011-03-340711","volume":"119","author":"A Astrakhan","year":"2012","unstructured":"Astrakhan, A. et al. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome. Blood119, 4395\u20134407 (2012).","journal-title":"Blood"},{"key":"17626_CR44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1074-7613(00)80590-7","volume":"9","author":"SB Snapper","year":"1998","unstructured":"Snapper, S. B. et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity9, 81\u201391 (1998).","journal-title":"Immunity"},{"key":"17626_CR45","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1084\/jem.190.9.1329","volume":"190","author":"J Zhang","year":"1999","unstructured":"Zhang, J. et al. Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. J. Exp. Med.190, 1329\u20131342 (1999).","journal-title":"J. Exp. Med."},{"key":"17626_CR46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/hum.2012.203","volume":"24","author":"A Cavazza","year":"2013","unstructured":"Cavazza, A., Moiani, A. & Mavilio, F. Mechanisms of retroviral integration and mutagenesis. Hum. Gene Ther.24, 119\u2013131, https:\/\/doi.org\/10.1089\/hum.2012.203 (2013).","journal-title":"Hum. Gene Ther."},{"key":"17626_CR47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/MOH.0b013e3282f30448","volume":"15","author":"LD Notarangelo","year":"2008","unstructured":"Notarangelo, L. D., Miao, C. H. & Ochs, H. D. Wiskott-Aldrich syndrome. Curr. Opin. Hematol.15, 30\u201336, https:\/\/doi.org\/10.1097\/MOH.0b013e3282f30448 (2008).","journal-title":"Curr. Opin. Hematol."},{"key":"17626_CR48","doi-asserted-by":"publisher","unstructured":"Perdomo, J., Yan, F., Leung, H. H. L. & Chong, B. H. Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells. J Vis. Exp., https:\/\/doi.org\/10.3791\/56420 (2017).","DOI":"10.3791\/56420"},{"key":"17626_CR49","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nbt.3583","volume":"34","author":"L Pinello","year":"2016","unstructured":"Pinello, L. et al. Analyzing CRISPR genome-editing experiments with CRISPResso. Nat. Biotechnol.34, 695\u2013697, https:\/\/doi.org\/10.1038\/nbt.3583 (2016).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17626-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17626-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17626-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T19:16:13Z","timestamp":1670267773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17626-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["17626"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-17626-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"assertion":[{"value":"26 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.J.T is on the Scientific Advisory Board of Orchard Therapeutics and Rocket Pharmaceuticals. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4034"}}